Eszopiclone

Indications

• FDA-approved for the treatment of insomnia in adults, improving both sleep latency and sleep maintenance in placebo-controlled trials.
• Unlike most hypnotics the label carries no explicit duration limit, and nightly efficacy has been demonstrated over six months of use.
• The 6-hour half-life makes it a reasonable choice when middle-of-the-night awakening rather than sleep onset is the dominant complaint.
• Cognitive behavioral therapy for insomnia remains first line by both American Academy of Sleep Medicine and American College of Physicians guidance.
• Off-label use in insomnia comorbid with depression or generalized anxiety has trial support as an adjunct to antidepressant therapy.
• Not indicated for pediatric insomnia; a controlled pediatric trial in children with ADHD-associated insomnia failed to show benefit.

Mechanism of action

• Cyclopyrrolone that acts as a positive allosteric modulator at the benzodiazepine site of GABA-A receptors, enhancing chloride conductance.
• It is the active S-enantiomer of zopiclone and binds a partly different domain than benzodiazepines, though the functional effect is similar.
• Less alpha-1 subunit selectivity than zolpidem, which contributes to a longer duration of action and some anxiolytic effect.
• Sleep architecture is largely preserved with modest reduction of REM latency changes compared with benzodiazepine hypnotics.
• Partial arousal from non-REM sleep with motor activity but no memory encoding underlies the complex sleep behaviors in the boxed warning.

Pharmacokinetics

• Rapidly absorbed with peak concentrations near 1 hour; a high-fat meal delays the peak by about an hour and blunts sleep-onset effect.
• Elimination half-life is roughly 6 hours in adults and lengthens to about 9 hours in older patients, raising next-day carryover risk.
• Oxidized and demethylated by CYP3A4 and CYP2E1 to desmethyl-eszopiclone, which is weakly active, and to an inactive N-oxide.
• Less than 10 percent is excreted unchanged in urine, so no dose adjustment is required for renal impairment at any stage.
• Severe hepatic impairment reduces clearance substantially and requires both a lower starting dose and a lower maximum dose.

Dosing

• Adults: start 1 mg PO immediately before bedtime with at least 7-8 hours of sleep opportunity remaining before planned awakening.
• May increase to 2 mg or 3 mg if clinically indicated; 3 mg is the labeled maximum and produces the most next-day impairment.
• Older adults or debilitated patients: start at 1 mg and do not exceed 2 mg, given prolonged half-life and greater sensitivity.
• Severe hepatic impairment: start at 1 mg and do not exceed 2 mg; the same limits apply when a strong CYP3A4 inhibitor is co-prescribed.
• Do not take with or immediately after a heavy or high-fat meal, since delayed absorption blunts the sleep-onset effect.
• Taper stepwise after prolonged nightly use rather than stopping abruptly, since rebound insomnia and withdrawal symptoms can occur.

Adverse effects

• Unpleasant metallic or bitter taste is the hallmark effect, reported by 8 percent at 1 mg and up to 34 percent at 3 mg, and often limits adherence.
• Headache in about 21 percent, somnolence 10 percent, dizziness 7 percent, dry mouth 7 percent and respiratory infection symptoms.
• Complex sleep behaviors including sleepwalking, sleep-driving and sleep-eating without recall, which mandate immediate permanent discontinuation.
• Next-morning psychomotor and driving impairment, demonstrated at 3 mg even when patients report feeling fully alert.
• Anterograde amnesia, hallucinations, abnormal thinking and behavior changes, plus worsening of depression and suicidal ideation.
• Angioedema and anaphylaxis can occur after the first dose, and respiratory depression is additive with opioids and alcohol.

Monitoring

• Ask directly at each visit about sleepwalking, sleep-driving, nocturnal eating and amnesia for nighttime events.
• Screen for and address sleep apnea, restless legs, alcohol use, chronic pain and untreated mood disorder before or alongside therapy.
• Assess next-morning alertness and warn against driving the following morning after the 3 mg dose in particular.
• Reassess response and continued need within 7-10 days; if insomnia persists beyond 7-10 days, evaluate for a comorbid condition.
• Check the prescription drug monitoring program and screen for substance use disorder before starting this schedule IV hypnotic.

Interactions

• Contraindicated in patients who have experienced a complex sleep behavior on eszopiclone and in known hypersensitivity or prior angioedema.
• Strong CYP3A4 inhibitors such as ketoconazole, ritonavir, clarithromycin and nefazodone roughly double exposure; cap the dose at 2 mg.
• Rifampin, carbamazepine and St. John's wort induce CYP3A4 and can reduce eszopiclone exposure enough to eliminate benefit.
• Additive sedation and respiratory depression with opioids, alcohol, benzodiazepines, gabapentinoids and sedating antihistamines.
• Olanzapine co-administration reduced psychomotor performance in study conditions, so combine sedating psychotropics cautiously.

Special populations

• Pregnancy: limited human data; late third-trimester exposure carries theoretical risk of neonatal sedation and respiratory depression.
• Lactation: it is not known whether eszopiclone is excreted in human milk; monitor the infant for sedation if breastfeeding continues.
• Pediatrics: safety and effectiveness under age 18 are not established and a pediatric trial did not demonstrate efficacy.
• Older adults: the AGS Beers Criteria advise avoiding Z-drugs because of delirium, falls, fractures and motor vehicle crashes.
• Hepatic and renal impairment: cap at 2 mg in severe hepatic disease; no adjustment is required at any level of renal impairment.

Clinical pearls

• The metallic aftertaste is the most common reason patients quit; warn them before the first dose.
• One of the few hypnotics with placebo-controlled nightly efficacy data out to six months.
• Avoid dosing after a heavy meal; delayed absorption defeats the sleep-onset effect entirely.